ArticleOpen forum infectious diseases2017
Prevalence of Carbapenem-Resistant Gram-Negative Infections in the United States Predominated by
Article in Open forum infectious diseases, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 100 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
100 citing papers in PubMed, 3 syntheses or guidelines pooled it, 194 citations in OpenAlex.
- Efficiency of combination therapy versus monotherapy for the treatment of infections due to carbapenem-resistant Gram-negative bacteria: a systematic review and meta-analysis.Systematic reviews · 2024Pooled it
- A systematic review and meta-analysis of carbapenem-resistant Enterobacteriaceae in West Africa.BMC medical genomics · 2024Pooled it
- A systematic review: the current status of carbapenem resistance in East Africa.BMC research notes · 2018Pooled it
- Single- and Multiple-Ascending-Dose Study of the Safety, Tolerability, and Pharmacokinetics of the Polymyxin Derivative SPR206.Antimicrobial agents and chemotherapy · 2021Trial
- Safety, Pharmacokinetics, and Drug-Drug Interaction Potential of Intravenous Durlobactam, a β-Lactamase Inhibitor, in Healthy Subjects.Antimicrobial agents and chemotherapy · 2020Trial
- Comparison of Treatment Outcomes between Analysis Populations in the RESTORE-IMI 1 Phase 3 Trial of Imipenem-Cilastatin-Relebactam versus Colistin plus Imipenem-Cilastatin in Patients with Imipenem-Nonsusceptible Bacterial Infections.Antimicrobial agents and chemotherapy · 2020Trial
- Pharmacokinetics and Tolerability of Intravenous Sulbactam-Durlobactam with Imipenem-Cilastatin in Hospitalized Adults with Complicated Urinary Tract Infections, Including Acute Pyelonephritis.Antimicrobial agents and chemotherapy · 2020Trial
- Assessing the Synergistic Potential of Ceftazidime-avibactam and Aztreonam against Metallo-beta-lactamase Producing Enterobacterales by Disc Elution and Disc E Strip - Synergy Method.Annals of African medicine · 2026Article
- Long-term epidemiology of bacterial pathogens and antimicrobial resistance in a secondary hospital in China: a 12-year retrospective study.BMC microbiology · 2026Article
- Clinical Characteristics of Carbapenem-Resistant Gram-Negative Bloodstream Infections and Fungemia Among High-Risk Pediatric Patients Receiving Empirical Antifungal Therapy.Pathogens (Basel, Switzerland) · 2026Observational
- Efficacy and safety of intravenous combined with aerosolized colistimethate sodium for carbapenem-resistant organism-induced pneumonia: a retrospective study.Annals of clinical microbiology and antimicrobials · 2026Observational
- Carbapenem-resistant Gram-negative bacilli infections in Japanese patients with cancer.Scientific reports · 2026Observational
- Genomic characterisation of extensively drug-resistant Acinetobacter baumannii isolates from a tertiary hospital in Ghana.PloS one · 2026Article
- Whole-genome sequencing reveals molecular characterization of carbapenem-resistantFrontiers in cellular and infection microbiology · 2026Article
- First nationwide survey onAntimicrobial agents and chemotherapy · 2025Article
- Comparative study of common over-the-counter wound care products against early and mature biofilms of antibiotic-resistant wound pathogens.JAC-antimicrobial resistance · 2025Article
- Prevalence and molecular characterisation of multi-drug resistant ST11 hypervirulent Klebsiella pneumoniae in a teaching hospital.BMC microbiology · 2025Article
- Molecular epidemiology and patient outcome of carbapenem-resistantJAC-antimicrobial resistance · 2025Article
- Antimicrobial Resistance and Mortality in Carbapenem-ResistantAntibiotics (Basel, Switzerland) · 2025Article
- Understanding and addressing β-lactam resistance mechanisms in gram-negative bacteria in Lebanon: A scoping review.Heliyon · 2025Review
40 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCarbapenem-resistant (CR) Gram-negative pathogens are recognized as a major health concern. This study examined the prevalence of infections due to 4 CR Gram-negative species (
methodsHospitalized patients with laboratory-confirmed infection due to any of the 4 Gram-negative pathogens were identified from the Premier Healthcare Database. Proportions of CR were calculated by pathogen and infection site (blood, respiratory, urinary, or other) for the United States as whole and by census regions. Crude and adjusted odds ratios for in-hospital mortality were produced using logistic regression.
resultsFrom 2009 to 2013, 13 262 (4.5%) of 292 742 infections due to these 4 Gram-negative pathogens were CR. Of these CR infections, 82.3% were caused by
conclusionThe majority of CR infections and disease burden in the United States was caused by nonfermenters
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.